# US 2023/0067644 A1 · Drg-mdm2-3 for use as a novel mouse double minute 2 (mdm2) inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0067644 A1
- Document ID: US20230067644A1
- Status: Published application
- Kind: A1
- Application number: 17/904,423
- Filed: 2021-02-17
- Published: 2023-03-02
- Earliest claimed: 2020-02-17
- Assignees: Bahcesehir Universitesi
- Applicants: Bahcesehir Universitesi
- Inventors: Serdar DURDAGI; Muge ORHAN; Timucin AVSAR; Maide PAKSOY; Gulsah AYDIN; Mine YURTSEVER
- Web page: https://patentgrep.com/patent/US20230067644A1

## CPC

- C07D 209/04: Indoles; Hydrogenated indoles
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07D 209/20: substituted additionally by nitrogen atoms, e.g. tryptophane
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to compound shown with formula (I) or a pharmaceutically acceptable derivative thereof for use as a novel inhibitor of MDM2 activity.

## Claims

### Claim 1

A compound shown with formula I which is DRG-MDM2_3, or a pharmaceutically acceptable derivative thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein pharmaceutically acceptable derivative of formula I can be its hydrates, solvates, prodrugs, all stereoisomers, salts, esters, tautomers, isotopically labeled derivatives or forms of compound of formula I that form under physiological conditions of the human body.

### Claim 3 (depends on 2)

A compound according to claim 2 wherein pharmaceutically acceptable derivative of compound of formula I is shown with formula Ia.

### Claim 4 (depends on 1, 2, 3)

A compound according to claims 1-3 wherein the compound is in the form of a 1:1 racemic mixture of R and S enantiomers.

### Claim 5 (depends on 1, 2, 3, 4)

A compound according to claims 1-4 for use in treatment of a disorder where p53-MDM2 interaction plays a role.

### Claim 6 (depends on 5)

A compound for use as claimed in claim 5 wherein the disorder is a proliferative disease.

### Claim 7 (depends on 6)

A compound for use as claimed in claim 6 wherein proliferative disease is cancer.

### Claim 8 (depends on 7)

A compound for use as claimed in claim 7 wherein cancer is benign or malignant tumors, a soft tissue sarcoma or a sarcoma (e.g. liposarcoma, rhabdomyosarcoma) or bone cancer (e.g. osteosarcomas), a carcinoma (e.g. such as of the brain, kidney, liver, adrenal gland, bladder, breast, gastric, ovary, colon, rectum, prostate, pancreas, lung, vagina or thyroid), a glioblastoma, meningioma, glioma, mesothelioma, a multiple myeloma, a gastrointestinal cancer (especially colon carcinoma or colorectal adenoma), a tumor of the head and neck, a melanoma, a prostate hyperplasia, a neoplasia, a neoplasia of epithelial character, a leukemia such as acute myeloid leukemia or B-cell chronic lymphocytic leukemia, a lymphoma (such as of B- or T-cell origin) and metastases in other organs

### Claim 9 (depends on 1, 2, 3, 4)

A compound according to claims 1-4 for use in combination with one or more additional pharmaceutically active agent.

### Claim 10 (depends on 9)

A compound for use as claimed in claim 9 wherein additional pharmaceutically active agent is selected from a group comprising anti-proliferative agents, immunomodulatory agents, antiviral agents, antimicrobial agents, anti-infective agents, anesthetic agents, antiemetics or combinations thereof.

### Claim 11 (depends on 10)

A compound for use as claimed in claim 10 wherein antiproliferative agents are selected from a group comprising alkylating agents, anthracyclines, taxanes (cytoskeletal disruptors), epothilones, histone deacetylase inhibitors, inhibitors of topoisomerase I, inhibitors of topoisomerase II, kinase inhibitors, tyrosine kinase inhibitors, nucleotide analogs and precursor analogs, peptide antibiotics, platinum based agents, retinoids, vincaalkaloids and derivatives or other agents.

### Claim 12 (depends on 1, 2, 3, 4)

A pharmaceutical composition comprising a compound according to claims 1-4 and at least one pharmaceutically acceptable excipient.

### Claim 13 (depends on 1, 2, 3, 4)

A pharmaceutical compositions comprising a compound according to claims 1-4 and one or more additional pharmaceutically active agent selected from a group comprising anti-proliferative agents, immunomodulatory agents, antiviral agents, antimicrobial agents, anti-infective agents, anesthetic agents, antiemetics or combinations thereof.
